FGTI-2734 attenuates Akt, mTOR, and c-Myc signaling activity and inhibits the growth of pancreatic cancer patient-derived xenografts with KRASG12D or KRASG12V mutation [42]. Here, AKT1 is linked to familial pancreatic carcinoma.